Trillium Asset Management LLC decreased its holdings in Biogen Inc (NASDAQ:BIIB) by 35.0% in the 1st quarter, HoldingsChannel reports. The firm owned 21,914 shares of the biotechnology company’s stock after selling 11,782 shares during the period. Trillium Asset Management LLC’s holdings in Biogen were worth $5,180,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of BIIB. Fox Run Management L.L.C. bought a new position in shares of Biogen during the 4th quarter valued at approximately $381,000. Vigilant Capital Management LLC increased its position in shares of Biogen by 16,087.4% during the 4th quarter. Vigilant Capital Management LLC now owns 35,936 shares of the biotechnology company’s stock valued at $10,814,000 after purchasing an additional 35,714 shares during the last quarter. Boston Advisors LLC grew its position in Biogen by 2.9% in the 4th quarter. Boston Advisors LLC now owns 1,091 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 31 shares during the last quarter. Highland Capital Management LLC grew its position in Biogen by 1.8% in the 4th quarter. Highland Capital Management LLC now owns 2,795 shares of the biotechnology company’s stock valued at $841,000 after acquiring an additional 49 shares during the last quarter. Finally, Oakbrook Investments LLC grew its position in Biogen by 23.6% in the 4th quarter. Oakbrook Investments LLC now owns 60,940 shares of the biotechnology company’s stock valued at $18,338,000 after acquiring an additional 11,635 shares during the last quarter. Institutional investors and hedge funds own 90.39% of the company’s stock.

A number of equities research analysts recently weighed in on BIIB shares. Barclays decreased their price objective on Biogen from $250.00 to $245.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Argus restated a “hold” rating on shares of Biogen in a research note on Tuesday, May 7th. Oppenheimer set a $290.00 target price on Biogen and gave the stock a “buy” rating in a report on Sunday, May 5th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Biogen in a report on Wednesday, April 24th. Finally, Mizuho set a $235.00 price objective on Biogen and gave the company a “hold” rating in a report on Monday, April 22nd. Two research analysts have rated the stock with a sell rating, twenty-three have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $288.96.

In other Biogen news, Director Alexander J. Denner acquired 50,342 shares of the stock in a transaction dated Tuesday, April 30th. The stock was acquired at an average cost of $229.25 per share, with a total value of $11,540,903.50. Following the transaction, the director now owns 10,909 shares in the company, valued at approximately $2,500,888.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Alexander J. Denner acquired 118,342 shares of the stock in a transaction dated Thursday, May 2nd. The shares were acquired at an average cost of $229.94 per share, with a total value of $27,211,559.48. Following the completion of the transaction, the director now owns 10,909 shares in the company, valued at approximately $2,508,415.46. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 173,035 shares of company stock valued at $39,759,632. Insiders own 0.29% of the company’s stock.

BIIB traded up $1.30 on Thursday, hitting $231.89. 38,186 shares of the company were exchanged, compared to its average volume of 2,098,261. The stock has a market capitalization of $44.71 billion, a price-to-earnings ratio of 8.85, a PEG ratio of 0.89 and a beta of 1.01. Biogen Inc has a twelve month low of $216.12 and a twelve month high of $388.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.84 and a quick ratio of 2.60.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $6.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $6.88 by $0.10. The business had revenue of $3.49 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Biogen had a return on equity of 41.39% and a net margin of 33.79%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.05 EPS. On average, research analysts anticipate that Biogen Inc will post 29.58 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/trillium-asset-management-llc-has-5-18-million-holdings-in-biogen-inc-biib/3012437.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Further Reading: Cryptocurrencies

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.